The term periodic fever syndrome has been used in a restricted sense to denote two diseases in which episodic fevers occur with a regular periodicity: cyclic neutropenia and the periodic fever, aphthous stomatitis, pharyngitis, and adenopathy (PFAPA) syndrome. Other authors have used the term in a more general sense to encompass a larger group of disorders characterized by recurrent episodes of fever that do not necessarily follow a strictly periodic pattern. These include familial Mediterranean fever, the autosomal dominant familial fevers (also known as Hibernian fever), and the hyperimmunoglobulin D syndrome. This article follows the latter usage, and reviews recent advances in our understanding of the genetics and molecular pathology of this group of diseases, as well as their clinical characterization and treatment.
Familial Mediterranean fever
Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by recurrent, self-limiting episodes of fever, often accompanied by serositis, oligoarticular arthritis and an erysipelas-like rash [1] . Most FMF patients derive from four ethnic groups (non-Ashkenazi Jews, Turks, Arabs, and Armenians), and the frequency of carriers can be as high as 1:5 among susceptible populations. interleukin-8, and interleukin-6 [12,13] . A leading hypothesis is that pyrin functions as a negative regulator of inflammation; this view is supported by recent data demonstrating that pyrin is preferentially expressed in inflammatory cells including neutrophils, eosinophils, and monocytes, and that the expression of pyrin is itself regulated by the cytokines interferon-γ and tumor necrosis factor, which play important roles in inflammatory pathways [14, 15] . 
Syndrome of periodic fever, aphthous stomatitis, pharyngitis, and adenopathy

Cyclic neutropenia
Both inherited and acquired forms of cyclic neutropenia have been described, in which episodes of severe neutropenia, often associated with fever and occurring with a period of 21 days, result from a periodic severe decline in the production of neutrophils from bone marrow. Horwitz et al. [20•] have recently identified mutations in the neutrophil elastase gene in patients with autosomal dominant cyclic neutropenia. A total of seven different mutations were observed in 13 families with the disorder. These mutations appear to interfere with the function of neutrophil elastase, but do not completely prevent its expression. The authors speculate that neutrophil elastase may participate in feedback control of neutrophil recruitment into the inflammatory response. Mathematical analysis of the patterns of hematopoietic cycling in patients with cyclic neutropenia supports the concept that a defect in such a feedback system may give rise to periodic cycling of neutrophil production [21•].
Hyper-IgD syndrome
Hyper-IgD syndrome (HIDS) is a recessively inherited condition first described in 1984 [22] and characterized by recurrent fevers, often accompanied by chills, headache, cervical adenopathy, arthritis, and rash, and associated with a persistent polyclonal elevation of serum immunoglobulin D levels. Like FMF, HIDS attacks are self-limiting, and affected individuals are generally well between episodes. The onset of HIDS attacks is usually in infancy or very early childhood [23] . The attacks typically last 3 to 7 days, and recur with variable frequency; colchicine is usually ineffective in preventing recurrent attacks. Attacks tend to become less severe and less frequent with increasing age. The peroxisomal enzyme MVK that plays a key role in cholesterol metabolism. Mutations in MVK have previously been described in patients with mevalonic aciduria, a multisystem disorder associated with progressive neurologic dysfunction and other systemic manifestations [28, 29] . Houten et al. [27•] point out that there is some clinical overlap between HIDS and mevalonic aciduria, since recurrent fevers, rash, lymphadenopathy, gastrointestinal involvement, and arthralgia are all characteristic of both disorders. The two disorders are nevertheless distinguishable at the genetic and biochemical levels in several respects: 1) the recently identified MVK mutations associated with HIDS are different from the MVK mutations previously reported to cause mevalonic aciduria [28, 29] ; 2) urinary levels of mevalonic acid were at least 25-fold lower in patients with HIDS than in patients with mevalonic aciduria; and 3) there was higher residual MVK enzymatic activity in cells from patients with HIDS as compared with mevalonic aciduria. The relation between disordered mevalonate metabolism and the clinical features of HIDS, and the cause and pathophysiologic significance of elevated serum IgD in this condition remain to be determined.
Autosomal dominant periodic fever syndromes
The dominantly inherited conditions, familial Hibernian fever (FHF), first described in an Irish/Scottish family in 1982, and familial periodic fever (FPF), described in an Australian family of Scottish descent in 1998, were mapped to the same locus on chromosome 12 in 1998 [30, 31] . This locus contains the gene for one of the two tumor necrosis factor (TNF) receptors, p55, and McDermott et al. [32•] have now identified mutations in this gene in patients with both FHF and FPF. The mutations alter the extracellular portion of the p55 protein, and are associated with increased cell surface expression of this receptor on monocytes and polymorphs and with decreased shedding of soluble receptor. McDermott et al. [32•] suggest that these changes may lead to exaggerated inflammatory responses to TNF, and that agents that block the biologic effects of TNF, such as etanercept, may therefore be useful in treating FHF/FPF.
Conclusions
The past year has seen exciting developments in the understanding of periodic fever syndromes. The identification of the genetic basis of several of these disorders has opened up new avenues for research into their pathophysiology, and has brought new refinement to their clinical definition and classification. Continuing advances in this area are certain to enhance our understanding of these and other inflammatory diseases and of the basic mechanisms of inflammatory responses.
